<DOC>
	<DOCNO>NCT00470301</DOCNO>
	<brief_summary>Tipifarnib may stop growth breast cancer block enzyme need cell growth block blood flow tumor . Drugs use chemotherapy , paclitaxel , doxorubicin , cyclophosphamide , work different way stop growth tumor cell , either kill cell stop divide . Giving tipifarnib together combination chemotherapy may kill tumor cell . This phase I/II trial study side effect best dose tipifarnib give together combination chemotherapy see well work treat patient stage II stage III breast cancer .</brief_summary>
	<brief_title>Tipifarnib Combination Chemotherapy Treating Patients With Stage II Stage III Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine recommended phase II dose tipifarnib give together paclitaxel patient stage IIB-IIIC breast cancer . ( Phase I ) II . To determine pathologic complete remission rate ( include breast breast plus axillary node ) patient treat sequential paclitaxel tipifarnib follow dose-dense doxorubicin hydrochloride , cyclophosphamide , tipifarnib . ( Phase II ) III . To determine feasibility safety regimen patient . ( Phase I II ) OUTLINE : This multicenter , phase I , dose-escalation study tipifarnib follow phase II study . PHASE I : Paclitaxel plus tipifarnib : Patients receive paclitaxel IV 1 hour day 1 oral tipifarnib twice daily day 1-3 . Treatment repeat weekly 12 course absence disease progression unacceptable toxicity . Patients evidence disease progression 12 course proceed AC chemotherapy plus tipifarnib . Cohorts 3-6 patient receive escalate dos tipifarnib recommend phase II dose ( RTPD ) determine . The RTPD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . AC chemotherapy plus tipifarnib : Patients receive doxorubicin hydrochloride IV 5-10 minute cyclophosphamide IV 30-60 minute day 1 , oral tipifarnib twice daily day 2-7 , pegfilgrastim subcutaneously day 2 . Treatment repeat every 2 week 4 course absence disease progression unacceptable toxicity . PHASE II : Patients receive paclitaxel tipifarnib RTPD AC chemotherapy plus tipifarnib phase I . After completion AC plus tipifarnib ( phase ) , patient re-evaluated surgery ( i.e. , modify radical mastectomy , radical mastectomy , segmental mastectomy lumpectomy axillary lymph node dissection ) . After completion study treatment , patient follow every 6 month 5 year annually 5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms , Male</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma breast ; clinical stage IIB , IIIA , IIIB , IIIC disease At least 1 week since prior tamoxifen selective estrogen receptor modulator prevention indication ( e.g. , osteoporosis prior ductal carcinoma situ ) HER2/neunegative immunohistochemistry fluorescence situ hybridization ( FISH ) Hormone receptor status : Estrogen and/or progesterone receptorpositive* [ Note : *Patients enrol phase I portion trial may estrogen progesterone receptornegative disease ] Normal organ function include : WBC &gt; = 3,000/mm^3 Absolute neutrophil count &gt; = 1,500/mm^3 Platelet count &gt; = 100,000/mm^3 Bilirubin normal AST ALT = &lt; 2.5 time upper limit normal LVEF normal echocardiogram nuclear scan Creatinine normal OR Creatinine clearance &gt; = 60 mL/min FEV1 &gt; = 1 L* DLCO &gt; = 50 % * [ Note : *Only baseline CT scan chest show parenchymal lung disease OR history chronic obstructive pulmonary disease ] No prior chemotherapy , radiotherapy , definitive therapeutic surgery ( e.g. , mastectomy , lumpectomy , axillary dissection ) cancer prior sentinel lymph node biopsy malignancy allow No prior adjuvant chemotherapy previous breast malignancy No concurrent combination antiretroviral therapy HIVpositive patient No concurrent investigational agent No concurrent anticancer agent therapy ECOG performance status 01 Fertile patient must use effective contraception Exclusion criterion : No invasive malignancy within past 5 year except curatively treat basal cell squamous cell skin cancer carcinoma situ cervix No history allergic reaction attribute compound similar chemical biological composition tipifarnib study drug ( e.g. , imidazole quinolones ) No uncontrolled illness include , limited , follow : ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia psychiatric illness/social situation would preclude study compliance Not pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>